Markets

Agios (AGIO) Provides Pipeline Update, AG-221 in Focus

A generic image of a person with a pen in hand
Credit: Shutterstock photo

Agios PharmaceuticalsAGIO announced its pipeline development strategy for its lead cancer metabolism and rare genetic metabolic disorders programs at its R&D Day. Agios does not have any approved product in its portfolio. The company currently has several candidates in its pipeline including the IDH2 mutant inhibitor - AG-221, IDH1 mutant inhibitor - AG-120 and the pan-IDH mutant inhibitor - AG-881.

These three candidates aim to improve treatment outcomes for patients whose cancer carries IDH mutations, including acute myeloid leukemia (AML) and glioma. Agios has a global, strategic collaboration with Celgene CELG for three of its candidates - AG-221, AG-120 and AG-881. The terms of the collaboration are different for each of them. While Celgene has worldwide development and commercialization rights to AG-221, it has only ex-U.S. rights to AG-120.

Agios announced the initiation of an international, multi-center, open-label, randomized phase III study (IDHENTIFY) to compare the efficacy and safety of AG-221 versus conventional care regimens in patients above 60 years with IDH2 mutant-positive AML that is refractory to or relapsed after second- or third-line therapy.

The company also announced a frontline combination development strategy involving AG-221 and AG-120. For newly diagnosed AML patients eligible for intensive chemotherapy, the company plans to initiate a phase Ib combination study of either AG-221 or AG-120 with standard induction and consolidation chemotherapy by the end of 2015. For newly diagnosed AML patients not eligible for intensive chemotherapy, the company plans to initiate a phase I/II combination study of either AG-221 or AG-120 with Celegene's Vidaza in the first quarter of 2016.

The FDA has granted Fast Track designation to both AG-221and AG-120 in addition to an orphan drug status to AG-120.

Apart from these, Agios' pipeline also includes a PKR activator, AG-348, currently being evaluated in a phase II study for pyruvate kinase deficiency. The company announced the development of its second PKR activator, AG-519. The company plans to initiate a phase I study on AG-519 by the first quarter of 2016.

However, several companies including AstraZeneca AZN and Roche RHHBY are actively engaged in the development of therapies in the field of cancer metabolism. These companies could develop drugs which may provide significant competition to Agios' drugs (if approved).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

AGIOS PHARMACT (AGIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RHHBY AGIO AZN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More